Clinical trial · Interventional
Living Better With Advanced Breast Cancer: Feasibility Evaluation of an Online Supportive Intervention.
Living Better With Advanced Breast Cancer (LIBERATE) Phase II: Evaluating the Feasibility of a Supportive, Self-management Website in Women Living With Secondary Breast Cancer.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The LIBERATE intervention is a multi-component self-management, symptom monitoring and signposting website tailored to the supportive needs of women living with secondary breast cancer. Overall, this intervention aims to improve quality of life among this growing group of patients through targeted, tailored and accessible information and support. This randomised waiting list control trial aims to evaluate the feasibility of the clinically integrated LIBERATE intervention. Results of participants' online symptom monitoring questionnaires are integrated with their electronic patient record, enabling clinician review and follow up alongside participants' own self-management activities.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LIBERATE website | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention arm
- description
- 12 weeks access to LIBERATE online supportive intervention (dose not specified) including symptom monitoring questionnaire component, with questionnaire results integrated within electronic medical records for clinician review.
- interventionNames
- Other: LIBERATE website
- type
- NO_INTERVENTION
- label
- Waiting list control arm
- description
- Care and support as usual; no access to intervention. Placed on waiting list to receive intervention following study completion.
Primary outcomes (7)
- measure
- Number of participants with self-reported outcome data at 12 weeks.
- timeFrame
- 12 weeks.
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult females (aged 18 and over). * Diagnosed with secondary (metastatic, stage IV) breast cancer. * Access to the internet. Exclusion Criteria: * Exhibiting signs of overt psychopathology or cognitive dysfunction. * Current involvement in other clinical trials involving completion of QoL or other patient reported outcome measures.
References
Publications (0)
Data not yet available